SmithKline Beecham and Ribena: Keeping a Legendary Brand Relevant
By the end of the 1990s, Ribena had a problem most brands would envy. Everyone already knew it. A blackcurrant drink first developed in Bristol in 1938, it had been in Irish and British kitchen presses for generations. Parents bought it because their parents had. That is the enviable part. It is also the trap.
The old business2000 case study on this company was titled "A Legendary Brand Looks to the Future." It was not about factories or medicines. It was about a single strategic question that every established brand eventually faces.
The brand was the real asset
Start with what the company actually owned. SmithKline Beecham plc described itself as a world leading research-based pharmaceutical company, and on paper that is what it was. But sitting inside that pharma group were two consumer names that most people would recognise faster than any drug: Ribena and Lucozade.
Beecham had picked both up decades earlier. Lucozade in 1938, Ribena's maker in 1955. That is the quiet lesson before the loud one. A brand people trust is an asset that outlives the company that made it, the packaging it came in, and often the reason it was invented in the first place.
Ribena's origin is a case in point. During the Second World War, when citrus fruit stopped arriving, blackcurrants became a home-grown source of vitamin C, and the syrup was given to children as a wartime health measure. That is not why anyone buys it now. The product survived its own founding purpose. What carried forward was not the wartime logic. It was the trust.
The one question the case answers
How do you keep a brand people have trusted for generations feeling current, without breaking the exact thing that made it worth buying?
Get this wrong in one direction and the brand ages with its buyers. The people who loved it grow up, the drink stays fixed in their childhood, and the next generation files it under "my mother's cupboard." Get it wrong in the other direction and you chase relevance so hard you throw out the trust. New flavours, new positioning, a fresh coat of everything, and suddenly nobody knows what the brand is for. Both failures end the same way. A name everyone recognises and nobody reaches for.
The move: extend the brand, protect the core
The playbook here is brand extension done with discipline. You take the trust the name already carries and you stretch it into new formats, new occasions, and new shelves, while keeping the one promise at the centre untouched.
For Ribena that meant the brand appearing in more than the concentrated syrup a parent diluted at the sink. Ready-to-drink cartons for a lunchbox. Bottles for on the go. Different pack sizes for different moments in a day. The blackcurrant promise stayed constant. The number of ways to say yes to it multiplied.
Its sibling in the portfolio shows the bolder version of the same idea. Lucozade began life as a drink you were given when you were sick, sold on recovery. In the 1980s it was repositioned around energy and sport, and the same liquid found an entirely new reason to exist. That is brand development at full stretch. The name stayed. The meaning moved.
The mechanism underneath both is the same. A brand is a shortcut in the customer's head. It saves them the work of judging a product from scratch every time. Extension works when the new thing borrows that shortcut honestly. It fails when the new thing asks the customer to trust the name for something the name was never about.
Credit the strategy, name the trade-off
The upside is efficiency. Launching a fresh drink from nothing is slow and expensive, because you are buying awareness and trust one customer at a time. Extending a loved brand lets a new product start halfway up the hill. The recognition is already paid for.
The cost is exposure. Every extension spends a little of the trust it borrows. Stretch too far or too often and you thin the meaning until the name stands for nothing in particular. A brand that tries to be for everyone, on every occasion, in every format, quietly stops being the obvious choice for any of them. The discipline is knowing which doors the brand is allowed to walk through and which ones would cheapen it. Saying no to a plausible extension is harder than saying yes, and it matters more.
What happened next
This is later context, separate from the brand case above.
The company did not stay as SmithKline Beecham. It had been formed in 1989 from the merger of the UK's Beecham Group and the US's SmithKline Beckman. In January 2000 it announced a merger with Glaxo Wellcome, completed on 27 December 2000, and the combined business became GlaxoSmithKline, or GSK.
On the Irish manufacturing side, the footprint was in medicines rather than the drinks brands. A plant at Dungarvan, County Waterford, established in 1987, later produced Panadol and employed around 750 people. A bulk-actives site in Cork was sold to Thermo Fisher in 2018 for about 90 million euro. These are corporate and operational facts from the years after the original case, and none of them change the brand story that made Ribena worth studying in the first place.
The transferable lesson
You do not have to invent something new to grow. Very often the most valuable thing a business owns is a name customers already trust, and the real work is deciding how far that trust can travel without snapping.
If you are building something in Ireland, the pattern holds at any size. The reputation you earn with your first product is an asset, not a footnote. You can extend it into new lines, new formats, and new audiences, and you should. But every extension is a withdrawal from the same account. Spend it on things that fit the promise and the account grows. Spend it on anything that carries your name for a quick win and you find out, slowly then suddenly, that trust was the whole business.
For more on how established firms defend and stretch what they have built, see the case studies hub.